Wenli Tao

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

Anita Kapur, Robin O'Connor‐Semmes, Elizabeth K. Hussey et al. · BMC Pharmacology and Toxicology · 2013 · 51 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Opioid Receptor Modulation of Hedonic Taste Preference and Food Intake: A Single‐Dose Safety, Pharmacokinetic, and Pharmacodynamic Investigation With GSK1521498, a Novel μ‐Opioid Receptor Inverse Agonist

Pradeep J. Nathan, Barry V. O’Neill, Mark Bush et al. · The Journal of Clinical Pharmacology · 2011 · 49 citations

Medicine, Pharmacokinetics, Pharmacology +17

Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies

James Sigafoos, Gary D. Bowers, Stephen Castellino et al. · Drug Metabolism and Disposition · 2012 · 43 citations

Medicine, Pharmacokinetics, Pharmacology +17

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

Elizabeth K. Hussey, Anita Kapur, Robin O'Connor‐Semmes et al. · BMC Pharmacology and Toxicology · 2013 · 37 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma

Gary T. Ferguson, Adel Mansur, Joshua Jacobs et al. · Journal of Asthma and Allergy · 2018 · 29 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14